National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 9) (PB 97 of 2017) (Cth)

PB 97 of 2017

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 9)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated         28 November 2017

LISA LA RANCE

Assistant Secretary

Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 9).

(2)   This Determination may also be cited as PB 97 of 2017.

1. Commencement

This Determination commences on 1 December 2017.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Doxepin

Omit

Dutasteride

[2]     Schedule 1, after item dealing with Fosaprepitant

Omit

Foscarnet

[3]     Schedule 1, after item dealing with Hydroxyurea

Omit

Hyoscine

[4]     Schedule 1, after item dealing with Ibandronic acid

Insert

Ibrutinib

[5]     Schedule 1, after item dealing with Milk powder – lactose free formula

Insert

Milk powder lactose intolerance formula

[6]     Schedule 1, after item dealing with Vismodegib

Insert

Vitamins, minerals and trace elements formula

[7]     Schedule 2, after item dealing with Duloxetine

Insert

Dutasteride

[8]     Schedule 2, after item dealing with Hydroxychloroquine

Insert

Hyoscine